BARS Institute translates GLRaV-3 and trunk disease into quantified NPV impairment, replant timing, and block-level capital priorities — structured for lenders, valuers, and transaction advisers.
Standard virus testing tells you a block is positive. It doesn't tell you what that means for recoverable value, lending security, or replant CAPEX. BARS Institute closes that gap — structured impairment evidence built specifically for the financial workflows that need it.
Financial outputs
Three outputs that RT-qPCR testing alone cannot produce. Each is derived from accredited diagnostics, epidemiological modelling, and discounted cashflow analysis.
Present-day financial impact of GLRaV-3 and trunk disease, expressed per hectare and as a percentage of clean vineyard value. Derived from a 10,000-run Monte Carlo simulation and reported as median and downside-risk outcomes.
Projects when each block will reach its economic replant threshold, based on current disease burden, trunk disease progression rate, and productive life remaining.
Ranks vineyard blocks by their contribution to total biological and financial risk, directing surveillance, remediation, and capital expenditure to the positions with the greatest economic consequence.
Supporting scientific metrics
RT-qPCR-confirmed GLRaV-3 prevalence expressed as a current-condition score from 0–100. Derived via Dorfman pooling inversion from ISO/IEC 17025 laboratory results.
Current trunk disease burden expressed as a score from 0–100, assessed across three tiers. Each figure carries a tier confidence label and disclosed uncertainty interval.
Expertise & Standards
BARS assessments are designed for agricultural lenders, registered valuers, accountants, and transaction advisers who need clear, defensible evidence on vineyard biological risk. The output is structured to support credit memoranda, impairment analysis, due diligence, and asset risk review.
Sarah Macfarlane, Founder and Lead Biological Risk Analyst, brings rare expertise spanning accredited plant virus diagnostics, vineyard health surveillance, and biological asset risk assessment. As a former IANZ-accredited Key Technical Person within an ISO/IEC 17025 laboratory, she has developed diagnostic quality systems, trained laboratory personnel, overseen plant virus testing programmes, and managed commercial grapevine health surveillance and reporting. Her experience spans the full spectrum of biological risk — from diagnostic detection through to vineyard-level asset management decisions.
BARS assessments follow a published methodology statement (MET-BARS-001), with all key assumptions, calibration bases, and sensitivity ranges disclosed. Diagnostic samples are submitted to independent IANZ-accredited laboratories for RT-qPCR analysis, supported by chain-of-custody documentation from collection through to laboratory receipt.
This framework supports vineyard impairment and fair value decision-making in line with NZ IAS 36, NZ IAS 41, NZ IFRS 13, and NZ IAS 16 considerations. It is designed to provide auditable biological risk evidence for professionals carrying financial or governance responsibility.
Tell us about the property, blocks, and context. We'll confirm scope and fee within one business day.
Request an assessment →BARS outputs are decision-support evidence for engaging professionals. They do not replace a registered valuation, accounting opinion, or credit decision.